Clinical Trial Update: Safety Study of TAK-700 in Subjects With Prostate Cancer. [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 safety study of TAK-700 (orteronel) in prostate cancer patients is reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• TAK-700 (Orteronel)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Prostatic Neoplasms | Phase 1, Phase 2 | Status: COMPLETED